Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomySalicylamide
Identification
- Name
- Salicylamide
- Accession Number
- DB08797
- Type
- Small Molecule
- Groups
- Approved
- Description
Salicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties. Its medicinal uses are similar to those of aspirin. Salicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies
- Structure
- Synonyms
- 2-Carbamoylphenol
- 2-Carboxamidophenol
- 2-Hydroxybenzamide
- o-hydroxybenzamide
- OHB
- Salicilamida
- Salicylamidum
- Salicylic acid amide
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Exaprin Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1) Tablet Oral HART Health 1987-01-20 Not applicable US Extra Strength Pain Reliever Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1) Tablet Oral Redicare Llc 2017-10-01 Not applicable US Green Guard Pain and Ache Relief Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1) Tablet Oral Unifirst First Aid 2008-12-30 Not applicable US Medi First Pain Relief Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1) Tablet Oral Unifirst First Aid 2008-12-30 Not applicable US Medi First Plus Pain Zapper Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1) Tablet Oral Unifirst First Aid 2008-12-30 Not applicable US Pain Free Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1) Tablet Oral Afassco Inc. 2016-10-25 Not applicable US Pain Reliever Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) Tablet Oral Advanced First Aid, Inc. 2015-04-07 Not applicable US Pain Stopper Extra Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1) Tablet Oral North Safety Products 2012-03-07 2017-12-22 US Pain Stoppers Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1) Tablet Oral North Safety Products 2017-01-02 Not applicable US Pain Stoppers Regular Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1) Tablet Oral North Safety Products 2013-04-18 2017-12-22 US - Categories
- Acids, Carbocyclic
- Amides
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Benzene Derivatives
- Benzoates
- Central Nervous System Agents
- Cyclooxygenase Inhibitors
- Ligands
- Nervous System
- Peripheral Nervous System Agents
- Salicylic Acid and Derivatives
- Sensory System Agents
- UNII
- EM8BM710ZC
- CAS number
- 65-45-2
- Weight
- Average: 137.136
Monoisotopic: 137.047678473 - Chemical Formula
- C7H7NO2
- InChI Key
- SKZKKFZAGNVIMN-UHFFFAOYSA-N
- InChI
- InChI=1S/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10)
- IUPAC Name
- 2-hydroxybenzamide
- SMILES
- NC(=O)C1=CC=CC=C1O
Pharmacology
- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Oral, rat LD50: 1890 mg/kg
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when Salicylamide is combined with (4R)-limonene. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Salicylamide is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Salicylamide is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Salicylamide is combined with 5-androstenedione. Experimental, Illicit Abciximab Salicylamide may increase the anticoagulant activities of Abciximab. Approved Acebutolol Salicylamide may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Salicylamide. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Salicylamide is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Salicylamide may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Salicylamide. Approved, Vet Approved Aclarubicin Salicylamide may decrease the excretion rate of Aclarubicin which could result in a higher serum level. Investigational Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Salicylamide. Approved Alclofenac The risk or severity of adverse effects can be increased when Salicylamide is combined with Alclofenac. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Salicylamide is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Salicylamide is combined with Aldosterone. Experimental, Investigational Aldoxorubicin Salicylamide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Alendronic acid The risk or severity of adverse effects can be increased when Salicylamide is combined with Alendronic acid. Approved Aliskiren Salicylamide may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Salicylamide is combined with Alminoprofen. Experimental Alprenolol Salicylamide may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Salicylamide. Approved, Investigational Amcinonide The risk or severity of adverse effects can be increased when Salicylamide is combined with Amcinonide. Approved Amikacin Salicylamide may decrease the excretion rate of Amikacin which could result in a higher serum level. Approved, Investigational, Vet Approved Amiloride Salicylamide may decrease the antihypertensive activities of Amiloride. Approved Amrubicin Salicylamide may decrease the excretion rate of Amrubicin which could result in a higher serum level. Approved, Investigational Ancrod Salicylamide may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Salicylamide. Investigational Androstenedione The risk or severity of adverse effects can be increased when Salicylamide is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Salicylamide is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Salicylamide is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Salicylamide is combined with Anisodamine. Investigational Annamycin Salicylamide may decrease the excretion rate of Annamycin which could result in a higher serum level. Investigational Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Salicylamide. Approved, Investigational Antithrombin III human Salicylamide may increase the anticoagulant activities of Antithrombin III human. Approved Apixaban Salicylamide may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Salicylamide is combined with Apocynin. Investigational Apramycin Salicylamide may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Salicylamide. Approved, Investigational Arbekacin Salicylamide may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Salicylamide may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Salicylamide may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Salicylamide may decrease the antihypertensive activities of Arotinolol. Investigational Atamestane The risk or severity of adverse effects can be increased when Salicylamide is combined with Atamestane. Investigational Atenolol Salicylamide may decrease the antihypertensive activities of Atenolol. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Salicylamide. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Salicylamide. Approved Azficel-T The risk or severity of adverse effects can be increased when Salicylamide is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salicylamide. Approved, Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Salicylamide. Investigational Balsalazide Salicylamide may increase the nephrotoxic activities of Balsalazide. Approved, Investigational Becaplermin Salicylamide may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Salicylamide is combined with Beclomethasone dipropionate. Approved, Investigational Befunolol Salicylamide may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Salicylamide may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when Salicylamide is combined with Benazepril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Salicylamide is combined with Bendazac. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salicylamide. Approved Benorilate The risk or severity of adverse effects can be increased when Salicylamide is combined with Benorilate. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Salicylamide. Withdrawn Benzydamine The risk or severity of adverse effects can be increased when Salicylamide is combined with Benzydamine. Approved Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Salicylamide. Investigational Betamethasone The risk or severity of adverse effects can be increased when Salicylamide is combined with Betamethasone. Approved, Vet Approved Betaxolol Salicylamide may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Salicylamide. Approved, Investigational Bevantolol Salicylamide may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Salicylamide is combined with Bevonium. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Salicylamide. Approved, Investigational Bisoprolol Salicylamide may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Salicylamide may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Salicylamide may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Salicylamide. Approved Bucillamine The risk or severity of adverse effects can be increased when Salicylamide is combined with Bucillamine. Investigational Bucindolol Salicylamide may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of adverse effects can be increased when Salicylamide is combined with Budesonide. Approved Bufexamac The risk or severity of adverse effects can be increased when Salicylamide is combined with Bufexamac. Approved, Experimental Bufuralol Salicylamide may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Salicylamide is combined with Bumadizone. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Salicylamide. Approved Bupranolol Salicylamide may decrease the antihypertensive activities of Bupranolol. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Salicylamide. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Salicylamide. Approved Candoxatril The risk or severity of adverse effects can be increased when Salicylamide is combined with Candoxatril. Experimental Captopril The risk or severity of adverse effects can be increased when Salicylamide is combined with Captopril. Approved Carbaspirin calcium The risk or severity of adverse effects can be increased when Salicylamide is combined with Carbaspirin calcium. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Salicylamide. Approved Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Salicylamide. Approved, Vet Approved, Withdrawn Carteolol Salicylamide may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Salicylamide may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Salicylamide. Experimental Celecoxib The risk or severity of adverse effects can be increased when Salicylamide is combined with Celecoxib. Approved, Investigational Celiprolol Salicylamide may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Certoparin Salicylamide may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Salicylamide. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylamide. Approved, Vet Approved Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salicylamide. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Salicylamide. Approved Ciclesonide The risk or severity of adverse effects can be increased when Salicylamide is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Salicylamide is combined with Cilazapril. Approved Cinoxacin Salicylamide may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Citric Acid Salicylamide may increase the anticoagulant activities of Citric Acid. Approved, Nutraceutical, Vet Approved Clobetasol The risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Salicylamide is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Salicylamide is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Salicylamide is combined with Clonixin. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Salicylamide. Vet Approved Cloranolol Salicylamide may decrease the antihypertensive activities of Cloranolol. Experimental Colesevelam Colesevelam can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Salicylamide is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Salicylamide is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Salicylamide is combined with Cortisone acetate. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when Salicylamide is combined with Curcumin. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Salicylamide. Experimental Cyclosporine Salicylamide may increase the nephrotoxic activities of Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Salicylamide may increase the anticoagulant activities of Dabigatran etexilate. Approved Dalteparin Salicylamide may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Salicylamide may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Salicylamide may increase the anticoagulant activities of Darexaban. Investigational Daunorubicin Salicylamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Approved Deferasirox The risk or severity of adverse effects can be increased when Salicylamide is combined with Deferasirox. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Salicylamide is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Salicylamide is combined with Delapril. Experimental Desirudin Salicylamide may increase the anticoagulant activities of Desirudin. Approved Desmopressin The risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin. Approved Desonide The risk or severity of adverse effects can be increased when Salicylamide is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Salicylamide is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Salicylamide is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Salicylamide is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Dexamethasone The risk or severity of adverse effects can be increased when Salicylamide is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Salicylamide is combined with Dexamethasone isonicotinate. Vet Approved Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Salicylamide. Approved, Investigational Dextran Salicylamide may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dextran 40 Salicylamide may increase the anticoagulant activities of Dextran 40. Approved Dextran 70 Salicylamide may increase the anticoagulant activities of Dextran 70. Approved Dextran 75 Salicylamide may increase the anticoagulant activities of Dextran 75. Approved Dibekacin Salicylamide may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Salicylamide is combined with Dibotermin alfa. Approved, Investigational Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Salicylamide. Approved, Vet Approved Dicoumarol Salicylamide may increase the anticoagulant activities of Dicoumarol. Approved Difenpiramide The risk or severity of adverse effects can be increased when Salicylamide is combined with Difenpiramide. Experimental Diflorasone The risk or severity of adverse effects can be increased when Salicylamide is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Salicylamide. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Salicylamide is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Salicylamide is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Salicylamide. Approved Dihydrostreptomycin Salicylamide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Salicylamide. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Salicylamide. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Salicylamide. Approved Doxorubicin Salicylamide may decrease the excretion rate of Doxorubicin which could result in a higher serum level. Approved, Investigational Drospirenone Salicylamide may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Salicylamide is combined with Droxicam. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Salicylamide is combined with Duvelisib. Investigational E-6201 The risk or severity of adverse effects can be increased when Salicylamide is combined with E-6201. Investigational Edetic Acid Salicylamide may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Salicylamide may increase the anticoagulant activities of Edoxaban. Approved Enalapril The risk or severity of adverse effects can be increased when Salicylamide is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Salicylamide is combined with Enalaprilat. Approved Enoxacin Salicylamide may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin Salicylamide may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Salicylamide. Experimental Epanolol Salicylamide may decrease the antihypertensive activities of Epanolol. Experimental Epirizole The risk or severity of adverse effects can be increased when Salicylamide is combined with Epirizole. Approved Epirubicin Salicylamide may decrease the excretion rate of Epirubicin which could result in a higher serum level. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Salicylamide. Experimental Eplerenone Salicylamide may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salicylamide. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Salicylamide. Approved Equilenin The risk or severity of adverse effects can be increased when Salicylamide is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Salicylamide is combined with Equilin. Approved Esmolol Salicylamide may decrease the antihypertensive activities of Esmolol. Approved Estrone The risk or severity of adverse effects can be increased when Salicylamide is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Salicylamide is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salicylamide. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Salicylamide. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Ethenzamide. Experimental Ethyl biscoumacetate Salicylamide may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Salicylamide is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when Salicylamide is combined with Etodolac. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Salicylamide is combined with Etofenamate. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Salicylamide is combined with Etoricoxib. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Salicylamide is combined with Evening primrose oil. Approved, Investigational Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Salicylamide. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Salicylamide. Experimental Fenbufen The risk or severity of adverse effects can be increased when Salicylamide is combined with Fenbufen. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Salicylamide. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Salicylamide. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Salicylamide is combined with Fentiazac. Experimental Feprazone The risk or severity of adverse effects can be increased when Salicylamide is combined with Feprazone. Experimental Ferulic acid Salicylamide may increase the anticoagulant activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Salicylamide. Approved, Investigational Fleroxacin Salicylamide may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Salicylamide. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluasterone. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Salicylamide is combined with Fludrocortisone. Approved, Investigational Fluindione Salicylamide may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Salicylamide may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Salicylamide is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Salicylamide is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when Salicylamide is combined with Flunixin. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Salicylamide is combined with Flunoxaprofen. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluorometholone. Approved, Investigational Fluprednidene The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Salicylamide. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Salicylamide is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salicylamide. Approved, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluticasone furoate. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluticasone propionate. Approved Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Salicylamide. Approved, Nutraceutical, Vet Approved Fondaparinux Salicylamide may increase the anticoagulant activities of Fondaparinux. Approved, Investigational Fondaparinux sodium Salicylamide may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Salicylamide. Experimental Formestane The risk or severity of adverse effects can be increased when Salicylamide is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of adverse effects can be increased when Salicylamide is combined with Fosinopril. Approved Framycetin Salicylamide may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide The therapeutic efficacy of Furosemide can be decreased when used in combination with Salicylamide. Approved, Vet Approved Gabexate Salicylamide may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Salicylamide may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Salicylamide may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Salicylamide. Approved, Withdrawn Gemifloxacin Salicylamide may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Salicylamide may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Gentamicin Salicylamide may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Salicylamide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental GPX-150 Salicylamide may decrease the excretion rate of GPX-150 which could result in a higher serum level. Investigational Grepafloxacin Salicylamide may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Salicylamide is combined with Guacetisal. Experimental Halcinonide The risk or severity of adverse effects can be increased when Salicylamide is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Salicylamide is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Salicylamide is combined with HE3286. Investigational Heparin Salicylamide may increase the anticoagulant activities of Heparin. Approved, Investigational Higenamine The risk or severity of adverse effects can be increased when Salicylamide is combined with Higenamine. Investigational Hydralazine Salicylamide may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salicylamide. Approved, Vet Approved Hydrocortisone The risk or severity of adverse effects can be increased when Salicylamide is combined with Hydrocortisone. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salicylamide. Approved, Investigational Hygromycin B Salicylamide may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of adverse effects can be increased when Salicylamide is combined with Ibandronate. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Salicylamide. Approved Ibuproxam The risk or severity of adverse effects can be increased when Salicylamide is combined with Ibuproxam. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Salicylamide. Approved, Investigational Idarubicin Salicylamide may decrease the excretion rate of Idarubicin which could result in a higher serum level. Approved Idraparinux Salicylamide may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Salicylamide. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Salicylamide is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Salicylamide is combined with Imidazole salicylate. Experimental Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylamide. Approved Indenolol Salicylamide may decrease the antihypertensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Salicylamide is combined with Indobufen. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylamide. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Salicylamide is combined with Indoprofen. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Salicylamide. Approved, Investigational Isepamicin Salicylamide may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Salicylamide is combined with Isoxicam. Withdrawn Istaroxime The risk or severity of adverse effects can be increased when Salicylamide is combined with Istaroxime. Investigational Kanamycin Salicylamide may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Salicylamide is combined with Kebuzone. Experimental Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Salicylamide. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Salicylamide. Approved Labetalol Salicylamide may decrease the antihypertensive activities of Labetalol. Approved Landiolol Salicylamide may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Salicylamide. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Salicylamide. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Salicylamide. Approved, Investigational Lepirudin Salicylamide may increase the anticoagulant activities of Lepirudin. Approved Letaxaban Salicylamide may increase the anticoagulant activities of Letaxaban. Investigational Levobunolol Salicylamide may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Salicylamide may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Salicylamide. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when Salicylamide is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Salicylamide is combined with Lisofylline. Investigational Lithium The serum concentration of Lithium can be increased when it is combined with Salicylamide. Approved Lonazolac The risk or severity of adverse effects can be increased when Salicylamide is combined with Lonazolac. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Salicylamide. Approved, Investigational Losartan The risk or severity of adverse effects can be increased when Losartan is combined with Salicylamide. Approved Loteprednol The risk or severity of adverse effects can be increased when Salicylamide is combined with Loteprednol. Approved Loxoprofen The risk or severity of adverse effects can be increased when Salicylamide is combined with Loxoprofen. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Salicylamide. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Salicylamide is combined with Lumiracoxib. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Salicylamide. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salicylamide. Approved Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Salicylamide. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Salicylamide is combined with ME-609. Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salicylamide. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Salicylamide is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salicylamide. Approved Melagatran Salicylamide may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Salicylamide is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylamide. Approved, Vet Approved Mepindolol Salicylamide may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine Salicylamide may increase the nephrotoxic activities of Mesalazine. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Salicylamide. Approved, Investigational, Withdrawn Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Salicylamide. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylamide. Approved Methylprednisolone The risk or severity of adverse effects can be increased when Salicylamide is combined with Methylprednisolone. Approved, Vet Approved Metipranolol Salicylamide may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylamide. Approved Metoprolol Salicylamide may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Metrizamide Salicylamide may decrease the excretion rate of Metrizamide which could result in a higher serum level. Approved Micronomicin Salicylamide may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Salicylamide. Approved, Experimental Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Salicylamide. Approved Mizoribine The risk or severity of adverse effects can be increased when Salicylamide is combined with Mizoribine. Investigational Moexipril The risk or severity of adverse effects can be increased when Salicylamide is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Salicylamide is combined with Mofebutazone. Experimental Mometasone The risk or severity of adverse effects can be increased when Salicylamide is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Salicylamide. Approved Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salicylamide. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salicylamide. Approved Nabumetone The risk or severity of adverse effects can be increased when Salicylamide is combined with Nabumetone. Approved Nadolol Salicylamide may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Salicylamide may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Salicylamide may increase the anticoagulant activities of Nafamostat. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Salicylamide. Approved Nalidixic Acid Salicylamide may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Salicylamide. Approved, Vet Approved NCX 1022 The risk or severity of adverse effects can be increased when Salicylamide is combined with NCX 1022. Investigational Neamine Salicylamide may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Salicylamide may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nemonoxacin Salicylamide may increase the neuroexcitatory activities of Nemonoxacin. Investigational Neomycin Salicylamide may decrease the excretion rate of Neomycin which could result in a higher serum level. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Salicylamide. Approved, Investigational Netilmicin Salicylamide may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Salicylamide is combined with Nifenazone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Salicylamide. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Salicylamide. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Salicylamide is combined with Nitroaspirin. Investigational Norfloxacin Salicylamide may increase the neuroexcitatory activities of Norfloxacin. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Salicylamide is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Salicylamide. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylamide. Approved Olsalazine Salicylamide may increase the nephrotoxic activities of Olsalazine. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Salicylamide is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Salicylamide is combined with Omapatrilat. Investigational Orgotein The risk or severity of adverse effects can be increased when Salicylamide is combined with Orgotein. Vet Approved Otamixaban Salicylamide may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Salicylamide. Approved Oxolinic acid Salicylamide may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Salicylamide may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Salicylamide. Approved, Withdrawn Pamidronate The risk or severity of adverse effects can be increased when Salicylamide is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Salicylamide is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Salicylamide is combined with Parecoxib. Approved Paromomycin Salicylamide may decrease the excretion rate of Paromomycin which could result in a higher serum level. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Salicylamide is combined with Parthenolide. Approved, Investigational Pazufloxacin Salicylamide may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Salicylamide may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol Salicylamide may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Salicylamide may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Salicylamide may increase the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The risk or severity of adverse effects can be increased when Salicylamide is combined with Perindopril. Approved Phenindione Salicylamide may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Salicylamide may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salicylamide. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salicylamide. Approved, Investigational Pindolol Salicylamide may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipemidic acid Salicylamide may increase the neuroexcitatory activities of Pipemidic acid. Experimental Pirarubicin Salicylamide may decrease the excretion rate of Pirarubicin which could result in a higher serum level. Investigational Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Salicylamide. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Salicylamide. Approved, Investigational Piromidic acid Salicylamide may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylamide. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Salicylamide is combined with Pirprofen. Experimental Pitolisant The risk or severity of adverse effects can be increased when Salicylamide is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Salicylamide may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Salicylamide may decrease the excretion rate of Plazomicin which could result in a higher serum level. Investigational Plicamycin Salicylamide may decrease the excretion rate of Plicamycin which could result in a higher serum level. Approved, Investigational, Withdrawn Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Salicylamide. Approved Practolol Salicylamide may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Salicylamide. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Salicylamide is combined with Pranoprofen. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Salicylamide is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Salicylamide is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Salicylamide is combined with Prednicarbate. Approved, Investigational Prednisolone The risk or severity of adverse effects can be increased when Salicylamide is combined with Prednisolone. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Salicylamide is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Salicylamide is combined with Pregnenolone. Approved, Experimental, Investigational Probenecid The serum concentration of Salicylamide can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Salicylamide is combined with Proglumetacin. Experimental Propacetamol The risk or severity of adverse effects can be increased when Salicylamide is combined with Propacetamol. Approved, Investigational Propranolol Salicylamide may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Salicylamide is combined with Propyphenazone. Experimental Proquazone The risk or severity of adverse effects can be increased when Salicylamide is combined with Proquazone. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Salicylamide. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Salicylamide. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Salicylamide. Vet Approved Protein C Salicylamide may increase the anticoagulant activities of Protein C. Approved Protein S human Salicylamide may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Salicylamide may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Salicylamide may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Salicylamide. Investigational Puromycin Salicylamide may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Quinapril The risk or severity of adverse effects can be increased when Salicylamide is combined with Quinapril. Approved, Investigational Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Salicylamide. Approved Ramipril The risk or severity of adverse effects can be increased when Salicylamide is combined with Ramipril. Approved Rescinnamine The risk or severity of adverse effects can be increased when Salicylamide is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylamide. Approved, Experimental, Investigational Reviparin Salicylamide may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Salicylamide may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Rimexolone The risk or severity of adverse effects can be increased when Salicylamide is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Salicylamide is combined with Risedronate. Approved, Investigational Rivaroxaban Salicylamide may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when Salicylamide is combined with Rofecoxib. Approved, Investigational, Withdrawn Rosoxacin Salicylamide may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rufloxacin Salicylamide may increase the neuroexcitatory activities of Rufloxacin. Experimental Sabarubicin Salicylamide may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Salicylamide. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Salicylamide. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Salicylamide. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Salicylamide. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Salicylamide. Investigational Sarilumab Sarilumab may increase the immunosuppressive activities of Salicylamide. Approved, Investigational Semapimod The risk or severity of adverse effects can be increased when Salicylamide is combined with Semapimod. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Salicylamide. Approved Serrapeptase The risk or severity of adverse effects can be increased when Salicylamide is combined with Serrapeptase. Investigational Sisomicin Salicylamide may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Salicylamide may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sodium phosphate Sodium phosphate may increase the nephrotoxic activities of Salicylamide. Approved Sotalol Salicylamide may decrease the antihypertensive activities of Sotalol. Approved SP1049C Salicylamide may decrease the excretion rate of SP1049C which could result in a higher serum level. Investigational Sparfloxacin Salicylamide may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spectinomycin Salicylamide may decrease the excretion rate of Spectinomycin which could result in a higher serum level. Approved, Investigational, Vet Approved Spirapril The risk or severity of adverse effects can be increased when Salicylamide is combined with Spirapril. Approved Spironolactone Salicylamide may decrease the antihypertensive activities of Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Salicylamide. Investigational Streptomycin Salicylamide may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Streptozocin Salicylamide may decrease the excretion rate of Streptozocin which could result in a higher serum level. Approved, Investigational Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salicylamide. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Salicylamide. Approved, Investigational Sulodexide Salicylamide may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Salicylamide. Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Salicylamide. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Salicylamide is combined with Suxibuzone. Experimental Tacrolimus Salicylamide may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Salicylamide. Approved Talinolol Salicylamide may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Salicylamide. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Salicylamide. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Salicylamide. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Salicylamide is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Salicylamide is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Salicylamide. Approved, Investigational Temafloxacin Salicylamide may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Salicylamide is combined with Temocapril. Experimental, Investigational Tenidap The risk or severity of adverse effects can be increased when Salicylamide is combined with Tenidap. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Salicylamide is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Salicylamide. Approved Tepoxalin The risk or severity of adverse effects can be increased when Salicylamide is combined with Tepoxalin. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Salicylamide is combined with Teriflunomide. Approved Tertatolol Salicylamide may decrease the antihypertensive activities of Tertatolol. Experimental Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Salicylamide. Approved Tiludronic acid The risk or severity of adverse effects can be increased when Salicylamide is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol Salicylamide may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Salicylamide is combined with Tinoridine. Investigational Tixocortol The risk or severity of adverse effects can be increased when Salicylamide is combined with Tixocortol. Approved, Withdrawn Tobramycin Salicylamide may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Salicylamide is combined with Tolfenamic Acid. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Salicylamide. Approved Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Salicylamide. Approved Trandolapril The risk or severity of adverse effects can be increased when Salicylamide is combined with Trandolapril. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Salicylamide. Approved, Investigational Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Salicylamide. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylamide. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Salicylamide is combined with Triamcinolone. Approved, Vet Approved Triamterene Salicylamide may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Salicylamide is combined with Tribenoside. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salicylamide. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Salicylamide is combined with Triptolide. Investigational Trovafloxacin Salicylamide may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin Salicylamide may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Salicylamide is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Salicylamide. Approved, Investigational Valdecoxib The risk or severity of adverse effects can be increased when Salicylamide is combined with Valdecoxib. Approved, Investigational, Withdrawn Valrubicin Salicylamide may decrease the excretion rate of Valrubicin which could result in a higher serum level. Approved Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Salicylamide. Approved, Investigational Vancomycin The serum concentration of Vancomycin can be increased when it is combined with Salicylamide. Approved Warfarin Salicylamide may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Salicylamide may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Salicylamide. Approved, Investigational Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Salicylamide. Approved, Investigational, Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Salicylamide is combined with Zofenopril. Experimental Zoledronic acid The risk or severity of adverse effects can be increased when Salicylamide is combined with Zoledronic acid. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Salicylamide. Withdrawn Zoptarelin doxorubicin Salicylamide may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level. Investigational Zorubicin Salicylamide may decrease the excretion rate of Zorubicin which could result in a higher serum level. Experimental - Food Interactions
- Not Available
References
- Synthesis Reference
Elijah J. Gold, Esther Babad, Lydia Peer, Wei K. Chang, "Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide." U.S. Patent US4658060, issued November, 1979.
US4658060- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015687
- PubChem Compound
- 5147
- PubChem Substance
- 99445267
- ChemSpider
- 4963
- BindingDB
- 50056900
- ChEBI
- 32114
- ChEMBL
- CHEMBL27577
- HET
- OHB
- Wikipedia
- Salicylamide
- ATC Codes
- N02BA75 — Salicylamide, combinations with psycholeptics
- N02BA — Salicylic acid and derivatives
- N02B — OTHER ANALGESICS AND ANTIPYRETICS
- N02 — ANALGESICS
- N — NERVOUS SYSTEM
- N02BA — Salicylic acid and derivatives
- N02B — OTHER ANALGESICS AND ANTIPYRETICS
- N02 — ANALGESICS
- N — NERVOUS SYSTEM
- PDB Entries
- 4k17
- MSDS
- Download (57 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 142 °C PhysProp boiling point (°C) 181.5 °C PhysProp water solubility 2060 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 1.28 HANSCH,C ET AL. (1995) pKa 8.37 (at 20 °C) KORTUM,G ET AL (1961) - Predicted Properties
Property Value Source Water Solubility 7.82 mg/mL ALOGPS logP 0.74 ALOGPS logP 1.17 ChemAxon logS -1.2 ALOGPS pKa (Strongest Acidic) 8.21 ChemAxon pKa (Strongest Basic) -1.8 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 63.32 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 37.12 m3·mol-1 ChemAxon Polarizability 13.22 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9877 Blood Brain Barrier + 0.9382 Caco-2 permeable + 0.6048 P-glycoprotein substrate Non-substrate 0.8565 P-glycoprotein inhibitor I Non-inhibitor 0.9817 P-glycoprotein inhibitor II Non-inhibitor 0.9948 Renal organic cation transporter Non-inhibitor 0.9178 CYP450 2C9 substrate Non-substrate 0.8207 CYP450 2D6 substrate Non-substrate 0.6203 CYP450 3A4 substrate Non-substrate 0.7067 CYP450 1A2 substrate Non-inhibitor 0.7061 CYP450 2C9 inhibitor Non-inhibitor 0.952 CYP450 2D6 inhibitor Non-inhibitor 0.9043 CYP450 2C19 inhibitor Non-inhibitor 0.8779 CYP450 3A4 inhibitor Non-inhibitor 0.8828 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9144 Ames test Non AMES toxic 0.9133 Carcinogenicity Non-carcinogens 0.864 Biodegradation Ready biodegradable 0.7192 Rat acute toxicity 2.1150 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9867 hERG inhibition (predictor II) Non-inhibitor 0.9468
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available GC-MS Spectrum - EI-B GC-MS splash10-00du-4900000000-f5a22e5a4fb556796bd9 GC-MS Spectrum - EI-B GC-MS splash10-00du-8900000000-701c75263149bd35390b Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available MS/MS Spectrum - , negative LC-MS/MS splash10-000i-1900000000-132217380eb9a2784eb0
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 1-hydroxy-4-unsubstituted benzenoids. These are phenols that are unsubstituted at the 4-position.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenols
- Sub Class
- 1-hydroxy-4-unsubstituted benzenoids
- Direct Parent
- 1-hydroxy-4-unsubstituted benzenoids
- Alternative Parents
- 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Carboximidic acids / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Hydrocarbon derivatives
- Substituents
- 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Monocyclic benzene moiety / Carboximidic acid derivative / Carboximidic acid / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Organooxygen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- phenols, salicylamides (CHEBI:32114) / a small molecule (SALICYLAMIDE)
Drug created on October 08, 2010 16:10 / Updated on March 02, 2018 03:42